跳至主要内容
临床试验/IRCT20121104011356N10
IRCT20121104011356N10招募中3 期

Effects of pentoxyfilline on serum markers of diabetic nephropathy in patients with type2 diabetes

ational Institute for Medical Research Development0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40 years 至 65 years(—)
性别
All

入选标准

  • type2 diabetes according to American Diabetes Association (ADA 2019)
  • with proteinuria

排除标准

  • infectious or malignant diseases
  • non-diabetic kidney disease
  • retinal hemorrhage
  • acute myocardial infarction or unstable angina
  • history of cardio-cerbro-vascular or peripheral artery disease
  • uncontrolled hypertension (i.e., systolic blood pressure [SBP] = 140mmHg and/or diastolic blood pressure [DBP] = 90 mmHg)
  • hyperthyroidism
  • history of hemodialysis
  • baseline serum potassium concentrations =5.5 meq/L
  • estimated glomerular filtration rate (eGFR) < 30mL/minute/1.73 m and pentoxifylline intolerance

研究者

发起方
ational Institute for Medical Research Development

相似试验